Clinical trials
Hospitalization clinical trials
Below are recruiting hospitalization clinical trials, each written for real people, not researchers. We’re tracking 15,641 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04312399Recruiting
Hormone treatment study for Alzheimer risk in postmenopausal women
This study looks at whether hormone treatment can help prevent or slow Alzheimer’s disease in women who have gone through menopause. It may help by testing a hormone-based approach in a carefully selected group.
GhentAges 40–65 - NCT04320680Recruiting
Study visits for adults with lupus in Brest, France
This study focuses on people aged 18 and older with lupus who attend a multi-team clinic visit in Brest, France. It mainly looks at whether you can participate in the multidisciplinary consultation and its related study procedures.
BrestAges 18–80 - NCT04314219RecruitingPhase 3
Preventing GVHD after leukemia stem cell transplant
This Phase 3 study tests whether giving post-transplant cyclophosphamide can better prevent a dangerous immune complication called GVHD compared with the usual standard medicines. You may be eligible if you are in remission from acute leukemia and planning a fully matched related-donor stem cell transplant.
RiyadhAges 14–65 - NCT04318678RecruitingPhase 1
CD123 CAR T-cell therapy for relapsed leukemia and related cancers
This early-phase study tests a lab-made immune therapy (CD123 CAR T cells) for children and young adults up to age 21 whose cancer has come back or didn’t respond to treatment. The goal is to see if these CAR T cells can find and attack cancer cells that carry a marker called CD123.
Memphis, TennesseeAges Up to 21 years - NCT04318730RecruitingPhase 2
Study of immunotherapy plus targeted drug for adrenal cancer
This trial tests whether combining camrelizumab (an immune treatment) with apatinib (a targeted drug) can shrink recurrent or metastatic adrenal cancer after standard treatment didn’t work. It may help some people control tumor growth when other treatments have already been tried.
Chengdu, SichuanAges 18 years+ - NCT04318899Recruiting
Studying who benefits in a specific borderline personality therapy program
This study looks at which factors predict how people do over time and how well they respond to a therapy program for borderline personality disorder. If you have a history of repeated self-harm, your experiences may help researchers understand who is most likely to improve—and why.
Oslo, OsloAges 12–70 - NCT04319627RecruitingPhase 3
Statins to prevent new blood clots after leg clot or lung clot
This trial tests whether taking a statin (rosuvastatin) after a recent leg blood clot (DVT) and/or lung blood clot (PE) can lower the chance of future venous clots. You might benefit if you’re at risk for more clotting and can take the study medication safely.
Calgary, AlbertaAges 18 years+ - NCT04320199Recruiting
Fermented beetle powder for alcohol-related liver problems
This trial tests whether a fermented powder made from a specific beetle can improve or protect the liver after alcohol-related liver injury. It’s looking for people with certain liver blood test levels, and it excludes several conditions and recent herbal or liver-affecting treatments.
Pusan, Ami-dongAges 19 years+ - NCT04320732Recruiting
Study COVID-19 spread at home and work
This study looks at what factors make COVID-19 spread more easily in the community and workplace. It may help researchers understand how to reduce transmission in everyday settings.
OsloAges 18 years+ - NCT04322578RecruitingPhase 2
Crizotinib versus standard chemotherapy for MET exon 14 lung cancer
This study compares crizotinib to standard chemotherapy for people with advanced (spread) non-small cell lung cancer that has a specific change called MET exon 14 skipping. The goal is to see which treatment works better and how safely it controls the cancer.
Changsha, HunanAges 18 years+ - NCT04324125Recruiting
Chemo plus immune therapy for HER2-positive advanced lung cancer
This trial studies whether adding an immune medicine (an antibody that helps your immune system recognize cancer, such as PD-1) to chemotherapy helps people with advanced HER2-positive non-small cell lung cancer. It may be aimed at people who have never had cancer treatment before.
Changsha, HunanAges 18 years+ - NCT04324151Recruiting
Pembrolizumab plus chemotherapy for lung cancer that may be removed
This trial tests whether adding pembrolizumab (an immune therapy) to standard chemotherapy helps people with certain non-squamous lung cancers that doctors think might be surgically removed. You might be considered if your planned treatment involves a “double platinum” chemotherapy or crizotinib and your cancer is potentially resectable.
Changsha, HunanAges 18 years+ - NCT04322617RecruitingPhase 2/Phase 3
Anlotinib plus immunotherapy for lung cancer after first treatment
This trial studies an oral targeted medicine (anlotinib) combined with an immunotherapy (checkpoint inhibitor) for lung cancer that did not respond to first-line chemo-immunotherapy. It may help shrink tumors and improve disease control after standard treatment has failed.
Changsha, HunanAges 18 years+ - NCT04322890RecruitingPhase 2
Study for advanced lung cancer with gene mutations
This Phase 2 trial studies treatment strategies for people with stage IV non-small cell lung cancer (NSCLC) who have certain cancer gene mutations (like EGFR, ALK, or ROS1). It aims to see how different treatments affect survival and tumor response.
Changsha, HunanAges 18 years+ - NCT04323371Recruiting
Study testing for heart-shock to reduce future events
This trial studies how to identify different types of “cardiogenic shock,” a serious drop in heart blood flow. It aims to use detailed patient information to guide care and possibly lower the chance of dangerous outcomes.
MilanAges 18–74 - NCT04323410Recruiting
Compare two ways to fix children’s forearm bone fractures
This study compares two surgical methods—casting versus percutaneous pinning—to treat certain distal (near the wrist) forearm fractures in children. It aims to find which method works best for healing and function, especially in specific fracture types.
HelsinkiAges Up to 10 years - NCT04324164Recruiting
Testing outcomes with EGFR pills for uncommon lung cancer mutations
This study looks at how well an EGFR-targeted pill (called an EGFR-TKI) works for people with advanced lung cancer that has an uncommon EGFR mutation. It may help doctors understand which patients benefit most and improve survival outcomes.
Changsha, HunanAges 18 years+ - NCT04324502Recruiting
Phone app study to collect symptom reports in NET
This study tests a mobile phone app that helps people with neuroendocrine tumors (NETs) report symptoms and quality of life. It may help by making it easier to track how you’re doing during treatment using questionnaires.
LondonAges 18 years+ - NCT04330118Recruiting
Study immune cells in DRESS and drug rash reactions
This trial studies how certain immune cells (eosinophils) behave during severe drug reactions like DRESS and during milder drug rashes. It may help doctors understand what drives organ damage and improve how these reactions are managed.
ArrasAges 18 years+ - NCT04330287Recruiting
Study of heart health in adults aging with HIV
This study looks at how aging affects heart health in people who have HIV. It may help researchers find better ways to prevent or monitor heart problems over time.
Essen, NordrheinwestfalenAges 18 years+ - NCT04330729Recruiting
Aspirin effect on blood clotting in kidney disease
This study checks how aspirin (also called salicylate) affects how platelets work, which helps blood clot. It involves people with advanced chronic kidney disease who are treated with Aranesp, and it may help guide safer care.
RoskildeAges 18–85 - NCT04330963Recruiting
Cohort study of causes of daytime sleepiness and sleepiness disorders
This study follows people with frequent daytime sleepiness (sometimes from narcolepsy or hypersomnia) and compares them with matched healthy people, including some with sleep apnea. The goal is to better understand what causes sleepiness and to improve how these conditions are recognized and measured.
BernAges 10–70 - NCT04331639Recruiting
High-dose vitamin D for kids with IBD on biologic therapy
This trial studies whether giving a higher dose of vitamin D3 helps children and teens with inflammatory bowel disease (Crohn’s or ulcerative colitis) who have low vitamin D levels. Participants are already on biologic medicines and will be treated while monitoring blood (and safety) related to vitamin D.
Boston, MassachusettsAges 5–25 - NCT04334031Recruiting
Hospital follow-up study for immune-related disease
This is a study that follows people with an immune-related illness at Lille University Hospital to better understand their care needs over time. By collecting information regularly, the study may help improve how future patients are monitored and treated.
LilleAges 18 years+
Hear when a new Hospitalization trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hospitalization?
- Yes. Clin2 currently lists 15,641 recruiting hospitalization studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hospitalization trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hospitalization trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.